Langerhans Cell Histiocytosis Clinical Trial
Official title:
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH)
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03270020 -
Denosumab for the Treatment of Adult LCH
|
Phase 2 | |
| Recruiting |
NCT05997602 -
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
|
Phase 2 | |
| Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
| Completed |
NCT03096782 -
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04120519 -
Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis
|
Phase 2 | |
| Not yet recruiting |
NCT05477446 -
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis
|
Phase 1 | |
| Recruiting |
NCT04121819 -
AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis
|
Phase 2 | |
| Recruiting |
NCT05284942 -
Central China Rosai-Dorfman Disease Registry
|
Phase 4 | |
| Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Completed |
NCT02608619 -
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
|
||
| Completed |
NCT01395004 -
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
|
Phase 2 | |
| Recruiting |
NCT02205762 -
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02425904 -
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
|
Phase 2 | |
| Recruiting |
NCT02670707 -
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
|
Phase 3 | |
| Completed |
NCT02665546 -
Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis
|
||
| Recruiting |
NCT04627090 -
LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study
|
||
| Recruiting |
NCT03585686 -
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
|
Phase 2 | |
| Recruiting |
NCT03155620 -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
|
Phase 2 | |
| Recruiting |
NCT04773366 -
A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol
|
Phase 3 | |
| Completed |
NCT02389400 -
Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis
|
Phase 2 |